Relapse-Free Survival and PD-L1 Expression in First High- and Low-Grade Relapsed Luminal, Basal and Double-Negative P53-Mutant Non-Muscular Invasive Bladder Cancer Depending on Previous Chemo- and Immunotherapy
The goal of this study was to assess how PD-L1 expression in tissue specimens of patients with main molecular subtypes of NMIBC (luminal, basal and double-negative p53-mutant) associates with relapsed-free survival in dependence on the tumor grade and prior treatment of primary bladder cancer. PD-L1...
Main Authors: | Ekaterina Blinova, Dmitry Enikeev, Dmitry Roshchin, Elena Samyshina, Olga Deryabina, Aleksander Tertychnyy, Dmitry Blinov, Evgenia Kogan, Marina Dudina, Haydar Barakat, Dmitrij Merinov, Aleksandr Kachmazov, Stanislav Serebrianyi, Natalia Potoldykova, Dmitrij Perepechin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/5/1316 |
Similar Items
-
Prognostic Role of <i>FGFR3</i> Expression Status and Tumor-Related MicroRNAs Level in Association with PD-L1 Expression in Primary Luminal Non-Muscular Invasive Bladder Carcinoma
by: Ekaterina Blinova, et al.
Published: (2020-11-01) -
Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma
by: Ekaterina Blinova, et al.
Published: (2021-09-01) -
Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment
by: Ekaterina Blinova, et al.
Published: (2019-05-01) -
Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC
by: Paolo Borghetti, et al.
Published: (2022-07-01) -
Characterizing the Relapse Potential in Different Luminal Subtypes of Breast Cancers with Functional Proteomics
by: Tung-Yi Lin, et al.
Published: (2020-08-01)